Insight Molecular Diagnostics Inc.

NasdaqCM:IMDX Stock Report

Market Cap: US$90.4m

Insight Molecular Diagnostics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:IMDX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
07 Feb 25BuyUS$2,209,080Patrick SmithIndividual1,077,600US$2.05
07 Feb 25BuyUS$200,000Andrea JamesIndividual97,561US$2.05
06 Feb 25BuyUS$1,353,424Broadwood Capital, Inc.Company660,207US$2.05
06 Feb 25BuyUS$9,236,250Broadwood Capital, Inc.Company4,505,488US$2.05
04 Feb 25BuyUS$51Patrick SmithIndividual25US$2.02
31 Jan 25BuyUS$1,789Patrick SmithIndividual890US$2.01
30 Jan 25BuyUS$8,438Patrick SmithIndividual4,198US$2.01
14 Jan 25BuyUS$34,114Patrick SmithIndividual16,055US$2.15
26 Dec 24BuyUS$26,350Andrew ArnoIndividual12,500US$2.11
26 Dec 24BuyUS$192,166Patrick SmithIndividual90,219US$2.13
05 Dec 24BuyUS$45,800Andrea JamesIndividual20,000US$2.29
02 Oct 24BuyUS$3,877,619Broadwood Capital, Inc.Company1,315,339US$2.95
02 Oct 24BuyUS$100,000Andrea JamesIndividual33,670US$2.97

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of IMDX?
Owner TypeNumber of SharesOwnership Percentage
Institutions1,871,7686.54%
Public Companies2,764,0789.66%
Individual Insiders3,847,53313.5%
General Public5,883,27620.6%
Hedge Funds14,232,63049.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 114%.

Top Shareholders

Top 25 shareholders own 79.38% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
39.9%
Broadwood Capital, Inc.
11,410,100US$36.1m82.7%2.47%
11.4%
Patrick Smith
3,258,485US$10.3m0%no data
9.87%
AWM Investment Company Inc
2,822,530US$8.9m264%1.09%
9.66%
Bio-Rad Laboratories, Inc.
2,764,078US$8.7m0%no data
3.31%
Pura Vida Investments, LLC
947,134US$3.0m44.7%20.13%
1.08%
John Gutfreund
310,272US$980.5k0%no data
0.93%
The Vanguard Group, Inc.
265,457US$838.8k9.6%no data
0.56%
Geode Capital Management, LLC
158,907US$502.1k15.9%no data
0.53%
Andrea James
151,231US$477.9k0%no data
0.34%
Andrew Arno
97,163US$307.0k0%no data
0.28%
BlackRock, Inc.
79,585US$251.5k-0.47%no data
0.26%
WealthEdge Investment Advisors LLC
73,971US$233.8k40.3%0.1%
0.22%
Morgan Stanley, Investment Banking and Brokerage Investments
61,708US$195.0k0%no data
0.17%
Citadel Advisors LLC
48,784US$154.2k0%no data
0.16%
Susquehanna International Group, LLP, Asset Management Arm
44,806US$141.6k0%no data
0.16%
Defender Capital LLC
44,378US$140.2k-5.74%0.05%
0.14%
FNY Investment Advisers, LLC
39,172US$123.8k-20.7%0.09%
0.1%
Northern Trust Global Investments
29,069US$91.9k67.7%no data
0.072%
Ekkehard Schutz
20,647US$65.2k69.3%no data
0.068%
State Street Global Advisors, Inc.
19,554US$61.8k0%no data
0.058%
Societe Generale, Securities Investments
16,585US$52.4k0%no data
0.047%
Millennium Management LLC
13,404US$42.4k0%no data
0.035%
Hudson River Trading LLC, Asset Management Arm
10,149US$32.1k0%no data
0.035%
Abaris Investment Management AG
10,000US$31.6k0%0.05%
0.016%
Andrew Last
4,509US$14.3k0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/20 20:16
End of Day Share Price 2025/06/18 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Insight Molecular Diagnostics Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Mark MassaroBTIG
Paul KnightJanney Montgomery Scott LLC
null nullKeyBanc Capital Markets Inc.